Forest Laboratories said it is postponing the launch of fibromyalgia treatment Savella until midyear, when the FDA is expected to respond to changes that Forest and partner Cypress Biosciences made to the drug's formula. Forest also announced that it will delay its application for FDA approval of aclidinium bromide, its candidate for chronic obstructive pulmonary disease, until additional clinical trials have been conducted.

Full Story:

Related Summaries